Kenvue Inc.
Kenvue Announces CEO Transition and Strategic Review
Summary
Kenvue Inc. announced a CEO transition with Thibaut Mongon stepping down and Kirk Perry appointed as interim CEO, effective immediately. The company also announced an ongoing comprehensive review of strategic alternatives to unlock shareholder value. Preliminary Q2 2025 results showed a 4.0% decline in net sales and organic sales down 4.2%. The company will report full Q2 2025 financial results and revise its full-year 2025 outlook on August 7, 2025.
Profitelligence Alerts
Get alerts for KVUE
Be first to know when Kenvue Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Kenvue Inc.
Kenvue Inc. is a consumer healthcare and pharmaceutical company. It focuses on delivering a range of health-centric products, spanning hygiene, pain relief, and other wellness categories. With deep-rooted expertise in pharmaceuticals, Kenvue Inc. targets the health and wellness needs of individuals, providing both prescription and over-the-counter solutions. The company has established itself as a vital entity in the consumer health sector, significantly impacting community health standards and individual lives. Positioned in the pharmaceutical industry, Kenvue Inc. collaborates with healthcare providers to enhance its product reach and efficacy. Its broad portfolio includes well-known brands and formulations that are trusted globally by consumers seeking reliable health solutions. As a player in this sector, Kenvue Inc. contributes to the enhancement of public health, highlighting its prominence in both domestic and international markets.
Official SEC Documents
Advertisement